Jeanmarie’s Illustrative Career In Leadership And Scientific Innovations

On April 2015, the media featured news about the first breakthrough of Amphivena Therapeutics Incorporation. The developments were in collaboration with Janseen Biotech on LinkedIn. The two parties tested the cancer antigen on a selected candidate to create the clinically perfect treatment for hematologic malignancies. The clinical candidate received certification from RECRUIT-TandAb and Affirmed GmbH. The results of the experiments proved successful, and Amphivena received an undisclosed amount to cover the costs of research, development, and labor. The chief executive officer and president of Amphivena Therapeutics, Jeanmarie Guenot, stated that the firm is enthusiastic to progress the cancer treatment medicines and therapies.

Jeanmarie Guenot utilizes her experience of more than 20 years in the biotechnological and pharmaceutical industries to lead Amphivena to achieve significant innovations for cancer. She previously worked for Atlas Venture as a venture capitalist, firm developer, and investment manager. After leaving Atlas, JeanMarie joined PDL BioPharma as the vice president of business and corporate development. Her role included overseeing the creation of licensing, acquisitions, alliance management, and mergers. She worked at Hoffman-La Roche between 2008 and 2009 as a chief scientist and business advisor before branching out as a solo scientist and entrepreneur. Jeanmarie Guenot facilitated the contract between Hoffman-La Roche and PDL to develop and commercialize drugs. As a result of her diligent and smart work, JeanMarie received the 2005 BioBusiness Network Innovative and Bio-Partnering award. In 2006, she won the Deal of Distinction from Licensing Executive Society.

In 2009, JeanMarie Guenot started SKS Ocular, LLC and managed it as a partner for three years. SKS Ocular specialized in developing technologies that create ocular drugs to treat glaucoma, macular degeneration, dry AMD and ocular inflammation. She has worked in firms in both the public and private platforms, specifically pharmaceutical R & D, corporate and commercial development enterprises, business development project and alliance development and venture capitalism. By working for SKS Ocular as the chief operating officer, JeanMarie honed her skills in developing ophthalmologic firms which she uses to expand Amphivena’s drug development works. JeanMarie studied at the University of California in San Francisco where he graduated with a degree in chemistry. After receiving her Ph.D. in the same field, she joined the Wharton School of the University of Pennsylvania to pursue and MBA.

Read more: Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies

Stephen Murray’s Loss Is Still Felt By His Family And Colleagues

Stephen Murray CCMP Capital, well-known private equity investor and former CEO of CCMP Capital Advisors died at home on March 12, 2015, at age 52. Due to health reason, he had recently resigned from the New York-based equity and buyout firm, formerly known as JP Morgan Partners.

The new CEO, Greg Brenneman, expressed his sympathy at the loss of a friend and terrific deal maker. Murray is survived by his wife and college sweetheart, their four sons, his parents and his brothers, his sister and their families.

Raised in Westchester County, a scenic New York City suburb, Murray attended Boston College and then went on to Columbia University where he earned his MBA. Murray’s career took off rapidly; he began as a credit trainee at Manufacturers Hanover.

In just four years, Murray rose to VP of Middle-Market Lending. After several mergers, Murray found himself working for JPMorgan as head of the firm’s buyout business and at JPMorgan Partners, which then became CCMP Capital Partners.

Back in 2007, Stephen Murray was CEO of a new company, minus the JPMorgan branding. CCMP Capital raised $3.4 billion in its first fundraising effort, with 80 percent of the money coming from outside investors.

This was due to Murray’s ability to build new relationships and reassure investors that CCMP had a good strategy and capability to execute it. At JPMorgan Partners, the average investment was $25 million, however, CCMP now handles deals with an average investment of $200 million.  Learn more about Stephen Murray CCMP Capital: http://fortune.com/2015/02/17/exclusive-ccmp-capital-ceo-stephen-murray-leaves-firm/
Stephen Murray was married to his wife Tami for 29 years. They raised their family in Stamford, CT, where Murray was known as a kind and compassionate man. He was active in numerous charities, including the Food Bank of Lower Fairfield County.

His commitment to the food bank was so great that Murray’s family asked mourners not to send flowers. Instead, the family asked people to send donations to the food bank.